Home » Codon Devices to Develop Therapeutic Proteins for Merrimack

Codon Devices to Develop Therapeutic Proteins for Merrimack

Apr 16, 2008
NEW YORK (GenomeWeb News) – Codon Devices will work with Merrimack Pharmaceuticals to develop therapeutic proteins under a research, development, and license agreement, Codon said today.
 
Codon will use its BioLogic platform to engineer proteins for specifications set by Merrimack, which is developing therapeutic products aimed at autoimmune disease and cancer.
 
Merrimack will pay Codon clinical milestone payments and royalties on net sales of any protein products that may result from the agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

Best Options

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

A Butterfly's Wings

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

This Week in PNAS

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Pathogen Tracking

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.